Galectin-3 activates PPARγ and supports white adipose tissue formation and high-fat diet-induced obesity

Endocrinology

Volumn 156, Issue 1, 2015, Pages 147-156

  Baek, Jung Hwan ^a,b   Kim, Seok Jun ^a,b   Kang, Hyeok Gu ^a,b   Lee, Hyun Woo ^a,b   Kim, Jung Hoon ^b   Hwang, Kyung A ^c   Song, Jaewhan ^b   Chun, Kyung Hee ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c National Institute of Animal Science   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; FATTY ACID BINDING PROTEIN 4; GALECTIN 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL; FAT INTAKE;

3T3 CELL LINE; ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY SIZE; CELL DIFFERENTIATION; CONTROLLED STUDY; EPIDIDYMIS FAT; FEMALE; GENE EXPRESSION; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; LIPID DIET; LIPOGENESIS; LIVER; MALE; MOUSE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; ANIMAL; CHEMICALLY INDUCED; CYTOLOGY; DOSE RESPONSE; FAT INTAKE; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HUMAN; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY;

3T3-L1 CELLS; ADIPOCYTES; ADIPOSE TISSUE, WHITE; ADIPOSITY; ANIMALS; CELL DIFFERENTIATION; DIETARY FATS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GALECTIN 3; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; MALE; MICE; MICE, KNOCKOUT; OBESITY; PPAR GAMMA;

EID: 84919754303     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1374     Document Type: Article

References (34)

1. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell. 2001;104(4):531-543
2. Steinberger J, Daniels SR, American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young); American Heart Association Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Obesity, insulin resistance, diabetes, and cardiovascular risk in children: An American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation. 2003;107(10):1448-1453
3. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: Importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab. 2004;89(6):2601-2607
4. Ahmadian M, Suh JM, Hah N, et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19(5):557-566
5. Kim TH, Kim MY, Jo SH, Park JM, Ahn YH. Modulation of the transcriptional activity of peroxisome proliferator-Activated receptor γ by protein-protein interactions and post-translational modifications. Yonsei Med J. 2013;54(3):545-559
6. Dutchak PA, Katafuchi T, Bookout AL, et al. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell. 2012;148(3):556-567
7. Dumic J, Dabelic S, Flogel M. Galectin-3: An open-ended story. Biochim Biophys Acta. 2006;1760(4):616-635
8. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005;5(1):29-41
9. Henderson NC, Sethi T. The regulation of inflammation by galectin- 3. Immunol Rev. 2009;230(1):160-171
10. Kiwaki K, Novak CM, Hsu DK, Liu FT, Levine JA. Galectin-3 stimulates preadipocyte proliferation and is up-regulated in growing adipose tissue. Obesity. 2007;15(1):32-39
11. Weigert J, Neumeier M, Wanninger J, et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab. 2010;95(3): 1404-1411
12. Rhodes DH, Pini M, Castellanos KJ, et al. Adipose tissue-specific modulation of galectin expression in lean and obese mice: Evidence for regulatory function. Obesity. 2013;21(2):310-319
13. Pang J, Rhodes DH, Pini M, et al. Increased adiposity, dysregulated glucose metabolism and systemic inflammation in Galectin-3 KO mice. PloS One. 2013;8(2):e57915
14. Pejnovic NN, Pantic JM, Jovanovic IP, et al. Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets. Diabetes. 2013;62(6): 1932-1944
15. HsuDK,Yang RY, Pan Z, et al. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol. 2000;156(3):1073-1083
16. Kim SJ, Hwang JA, Ro JY, Lee YS, Chun KH. Galectin-7 is epigenetically- regulated tumor suppressor in gastric cancer. Oncotarget. 2013;4(9):1461-1471
17. Ko A, Shin JY, Seo J, et al. Acceleration of gastric tumorigenesis through MKRN1-mediated posttranslational regulation of p14ARF. J Natl Cancer Inst. 2012;104(21):1660-1672
18. Kim JH, Park KW, Lee EW, et al. Suppression of PPARγ through MKRN1-mediated ubiquitination and degradation prevents adipocyte differentiation. Cell Death Differ. 2014;21(4):594-603
19. Kim SJ, OH JS, Shin JY, et al. Development of microRNA-145 for therapeutic application in breast cancer. J Control Release. 2011; 155(3):427-434
20. Kim SJ, Shin JY, Cheong TC, Cet al. Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of betacatenin in gastric cancer. Clin Exp Metastasis. 2011;28(8):743-750
21. Wang YG, Kim SJ, Baek JH, Lee HW, Jeong SY, Chun KH. Galectin- 3 increases the motility of mouse melanoma cells by regulating matrix metalloproteinase-1 expression. Exp Mol Med. 2012;44(6): 387-393
22. KimSJ, Choi IJ, CheongTC,et al. Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology. 2010;138(3):1035-1045
23. Ahn YH, Yi H, Shin JY, et al. STAT3 silencing enhances the efficacy of the HSV.tk suicide gene in gastrointestinal cancer therapy. Clin Exp Metastasis. 2012;29(4):359-369
24. Cheong TC, Shin JY, Chun KH. Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents. Cancer Sci. 2010;101(1):94-102
25. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226(1):497-509
26. Lumeng CN, Maillard I, Saltiel AR. T-ing up inflammation in fat. Nat Med. 2009;15(8):846-847
27. Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol. 2000;16:145-171
28. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA. 2006;103(13):5060-5065
29. Jiang JX, Chen X, Hsu DK, et al. Galectin-3 modulates phagocytosis- induced stellate cell activation and liver fibrosis in vivo. Am J Physiol Gastrointest Liver Physiol. 2012;302(4):G439-G446
30. Iacobini C, Menini S, Ricci C, et al. Galectin-3 ablation protects mice from diet-induced NASH: A major scavenging role for galectin-3 in liver. J Hepatol. 2011;54(5):975-983
31. Traber PG, Zomer E. Therapy of experimental NASH and fibrosis with galectin inhibitors. PloS One. 2013;8(12):e83481
32. Nomoto K, Tsuneyama K, Abdel et al. Disrupted galectin-3 causes non-Alcoholic fatty liver disease in male mice. J Pathol. 2006;210(4): 469-477
33. Zimmermann R, Strauss JG, Haemmerle G, et al. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science (New York, NY). 2004;306(5700):1383-1386
34. Haemmerle G, Lass A, Zimmermann R, et al. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science (New York, NY). 2006;312(5774):734-737.